American Heart Association - Scientific Sessions 2006. Cell therapies for ischemic tissues and treatments for lipid metabolism disorders.
Veryard
Claire
C
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. claire.veryard@thomson.com
D000818:Animals; D064987:Cell- and Tissue-Based Therapy; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000188:drug therapy; D042783:Endothelial Cells / Q000166:cytology; D004921:Erythropoietin / Q000008:administration & dosage; D005121:Extremities / Q000098:blood supply; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage; D006801:Humans; D007511:Ischemia / Q000628:therapy*; D052439:Lipid Metabolism Disorders / Q000628:therapy*; D009203:Myocardial Infarction / Q000628:therapy; D009525:Niacin / Q000009:adverse effects; D011341:Probucol / Q000031:analogs & derivatives / Q000627:therapeutic use
D008078:Cholesterol, LDL; D016222:Fibroblast Growth Factor 2; D004921:Erythropoietin; D009525:Niacin; C471047:succinobucol; D011341:Probucol